At a median follow-up of 60.9 months, median EFS was 74.1 months in the pembrolizumab arm and not reached in the placebo arm.
|Videos|December 28, 2022
2022 SUO Annual Meeting recap: Updates in intermediate-risk non–muscle-invasive bladder cancer
Author(s)Urology Times staff
Laura Bukavina, MD, MPH, summarizes a presentation from the 2022 Society of Urologic Oncology Annual Meeting from Sarah P. Psutka, MD, MS.
Advertisement
In this video, Laura Bukavina, MD, MPH, summarizes the 2022 Society of Urologic Oncology Annual Meeting presentation, “Intermediate-risk NMIBC: Updates on Trials & New Horizons.” Bukavina is a urologic oncology fellow at Fox Chase Cancer Center in Philadelphia, Pennsylvania.
Advertisement
Related to this article
Take a look through some of the notable data presentations at this year's ESMO Congress.
Advertisement
Advertisement
Trending on Urology Times
1
ESMO 2026: Key presentations across genitourinary oncology
2
Darolutamide associated with less cognitive change than enzalutamide in prostate cancer
3
How PSMA-PET shapes staging and recurrence workup in prostate cancer
4
KLK2-comPAS trial explores dual T-cell engagement in mCRPC
5